ANVS · Annovis Bio, Inc.
$1.21
+0.04 (+3.42%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Market Cap
$51.55M
Shares
42.61M
Volume · Oct 9
521.9K
Avg daily vol (3M)
880.06K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.21
Open$1.17
Day$1.14–1.24
52W close$1.04–5.10
Avg vol 30d1.2M
Short int5.9M · 13.8% float · 6.0d
Short vol66%
Last earningsAug 12, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-45.0%
Trailing year
Short interest
13.8%
Latest settlement · 6.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−19%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−37%
trailing
YTD return
−65%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
2 of 63 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.84% of float · ▼ -2.1% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−19%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Flat
2 of 63 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.84% of float · ▼ -2.1% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 4%
Range high $5
vs 200-day avg -43%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Common shares outstanding | 42.6M | as of June 30, 2026 | — |
| Parkinson's disease open-label extension activated clinical sites | 26 | second quarter ended June 30, 2026 | — |
| Parkinson's disease open-label extension estimated enrollment goal | 500 | second quarter ended June 30, 2026 | — |
| Parkinson's disease open-label extension study enrollment | 266 | second quarter ended June 30, 2026 | — |
| Phase 3 Alzheimer's disease trial enrollment | 850 | second quarter ended June 30, 2026 | — |
| Phase 3 Alzheimer's disease trial original target enrollment | 760 | second quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANVS
this stock
Annovis Bio, Inc.
|
$51.55M | -65.0% | — | — | 13.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANVS | +2.5% | +8.0% | -37.0% | -4.7% | -65.0% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | +1.4% | +6.2% | -46.8% | -6.8% | -79.2% |